43 results about "Chronic infectious disease" patented technology

The application discloses a kind of chronic infectious disease digital people health management system construction method, it relates to AIDS nursing management technical field.Based on Triangle model, the management classification and characteristics of HIV patients are determined by latent profile and association rule analysis, and it is embedded into applet using agile development;Based on the basic nursing framework, the commonality and difference of patients in different levels are explored Care needs;Through the preliminary construction of AIDS hierarchical case management program by range review and focus group interview, the final draft is formed by revising and improving through written evaluation and field demonstration, and the well-constructed management program is embedded into a digital human interaction platform based on artificial intelligence.The application protects the privacy of patients, alleviates the shortage of medical human resources, meets the growing health needs of HIV patients, improves patient satisfaction and improves the quality of HIV care services.

The invention belongs to the technical field of biological medicine, and discloses an anti-PD-L1 nano antibody and application thereof. And the amino acid sequences of CDR1-3 of the PD-L1 nano antibody are respectively shown as SEQ ID NO.2-4. The PD-L1 nano antibody is a PD-L1 antibody. The nano antibody can effectively block the combination of PD1 and PDL1, is high in affinity and strong in specificity, can be used for immunoblotting, enzyme-linked immunosorbent assay kits and flow cytometry counting, can also be used for treating diseases such as tumors, autoimmune diseases and chronic infectious diseases, and has the potential of being developed as an immune checkpoint inhibitor.

The present invention relates to a metal-organic framework for inhibiting the activity of M2 macrophages, and a pharmaceutical composition comprising same, wherein the metal-organic framework of the present invention is non-toxic to cells and can exhibit an effect of inhibiting the activity of M2 macrophages. More specifically, the metal-organic framework of the present invention can be provided as an anticancer composition for tumor-related macrophage-mediated diseases, particularly solid cancer, through the inhibition of M2 macrophages capable of increasing the expression of genes associated with parasite invasion, tissue remodeling, and tumor proliferation (immunomodulatory function), and can also be provided as a pharmaceutical composition for treating chronic infectious diseases, liver cirrhosis, obesity-related metabolic diseases, scar formation and idiopathic lung diseases.

The application belongs to the technical field of microorganisms, and discloses a method for inducing formation of living unculturable state bacteria in the presence of host cells and application thereof. The method is as follows: cells in the 3th to 20th generation are transferred to a well plate to obtain induced cells; bacteria in the logarithmic growth phase are washed by a buffer, and modified cell culture solution is resuspended to obtain a bacterial suspension. The bacterial suspension is added to the induced cells, and after incubation in a constant-temperature incubator for 1-5 hours, 10-500 mg / L gentamicin-containing modified cell culture solution is added. After cell treatment for 3-10 days, intracellular bacteria are collected by adding cell lysis solution, and then washed, centrifuged and resuspended to obtain living unculturable state bacteria. The application can induce bacteria to enter the living unculturable state in the presence of host cells, which not only expands the understanding of living unculturable state bacteria, but also provides theoretical and technical support for recurrent and chronic infectious diseases in clinical practice.